ImmunoGen Announces Departure of Sandra Poole
"I thank
"I greatly appreciate the opportunity I've had to work with such a
talented team of professionals, committed to delivering innovative
therapies to patients with cancer. ImmunoGen is at an exciting point in
its evolution and I'm confident the Company will continue to be a leader
in ADCs," said
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics using
its proprietary ADC technology. ImmunoGen's lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in
combination regimens for earlier-stage disease. ImmunoGen's ADC
technology is used in Roche's marketed product, Kadcyla®, in three other
clinical-stage ImmunoGen product candidates, and in programs in
development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis,
Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170123006039/en/
Investor Contact:
sarah.kiely@immunogen.com
or
Media
Contacts:
amy.reilly@immunogen.com
or
FTI
Consulting Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
Source:
News Provided by Acquire Media